Lantern Pharma Inc. (LTRN)
NASDAQ (CM) NASDAQ (CM) Primary Summary
LTRN Chart
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai AI Platform for Rare Cancer Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Discusses Live Demonstration of withZeta.ai Platform for AI-Driven Oncology Drug Discovery Transcript
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
Lantern Pharma Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Lyn Dippel Curio Wealth LLC | 2,000 | $6,060 | $5,760 | -$300 | -4.95% |
Lantern Pharma Inc. (LTRN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lantern Pharma Inc. ever had a stock split?
Lantern Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Panna Sharma CEO | NASDAQ (CM) Exchange | 51654W101 CUSIP |
| US Country | 16 Employees | - Last Dividend | - Last Split | 11 Jun 2020 IPO Date |
Overview
Lantern Pharma Inc. represents a pioneering force in the biotechnology industry, leveraging the convergence of artificial intelligence (AI), machine learning, and extensive genomic data to enhance and expedite the process of drug development. Established in 2013 and based in Dallas, Texas, the company is primarily engaged in clinical stage research, aiming to discover and develop innovative therapeutic solutions for a variety of cancers. By integrating advanced technologies into traditional biotechnological methods, Lantern Pharma aspires to make significant strides in the treatment of cancer and improve outcomes for patients worldwide.
Products and Services
- LP-300: Currently in phase 2 clinical trials, LP-300 is being studied as a combination therapy specifically for never-smokers diagnosed with non-small cell lung cancer adenocarcinoma. This product highlights Lantern Pharma's commitment to addressing niche patient populations within the broader cancer community.
- LP-184: In phase 1 clinical trials, LP-184 is under investigation for its potential to treat solid tumors, including those found in pancreatic, breast, bladder, and lung cancers, in addition to glioblastoma and other central nervous system cancers. This versatile compound signifies the company's approach to tackling a wide array of malignancies.
- LP-284: Also in phase 1 clinical testing, LP-284 is being explored as a treatment option for non-Hodgkin's lymphomas, including specific types like mantle cell lymphoma and double hit lymphoma. This development underscores Lantern's focus on hematologic cancers in addition to solid tumors.
- STAR-001: Currently in the preclinical development stage, STAR-001 is aimed at treating glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and is under consideration for pediatric rare disease designation. This initiative illustrates the company's dedication to combating some of the most challenging and deadly brain tumors.
- ADC Program: This program represents an innovative antibody drug conjugate therapeutic approach for cancer treatment, showcasing the company's efforts in developing targeted therapies that deliver cytotoxic agents directly to cancer cells while sparing healthy tissues.
In addition to these products, Lantern Pharma's proprietary artificial intelligence platform, RADR®, stands out as a significant service offering. RADR harnesses big data analytics and machine learning to optimize the drug development process by combining molecular data from various sources. This cutting-edge platform not only accelerates the development of new therapies but also aids in identifying the most promising drug candidates for further exploration.
